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ABSTRACT
Researchers have been trying to fight cancer with synthesis of new bioactive
compounds but many of these novel drugs have low solubility in water and it is difficult
to deliver them into a patient's body One way of solving this particular problem is to
use nanoscale drug delivery systems In this dissertation, we describe using an
ultrasonic assisted layer-by-layer encapsulation process to prepare anti-cancer drugs
with 50-200 ran particle size with designed coating to achieve sustained release and
target delivery
Two methods for systematic manufacture of low solubility anti-cancer drug
nanoparticles were proposed 1) Top-down approach to breakdown larger drug crystals
into nano-size particles 2) Bottom-up approach to fabricate nano size drug crystals
from a drug solution
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CHAPTER 1
INTRODUCTION
1 1 Motivation
Cancer is the second leading cause of death in the Umted States The National
Cancer Institute estimated that 1,529,560 men and women (789,620 men and 739,940
women) will be diagnosed with, and 569,490 men and women will die from various of
cancer m 2010 [1]
Researchers had been trying to fight cancer with new natural or synthetic
bioactive compounds Although these novel compounds showed promising results in
screening process, many of them exhibit low solubility in water because of the
hydrophobic and/or polycychc nature Low solubility often brings challenges to drug
administration, because the traditional formulation usually cannot provide enough of the
bioavailability required for treatment Also many of these compounds are highly toxic
to normal cells so targeted delivery of the drug to the tumor tissues is required One way
of solving the problem is to establish a drug delivery system that uses nano size drug
particles with appropriate coating Our project will use an ultrasonic assisted layer-bylayer encapsulation process to prepare anti-cancer drug with 50-200 nm size with a
designed coating to achieve sustained release and targeted delivery

1

2

1.2 Outlines
1.2.1 Objectives of the study
We developed the following directions in our work
1 We will systemically establish a process to fabricate nano size, low solubility
drug particles (pachtaxel and curcumin)
2 We will optimize the process established m 1 to reduce the drug particle size
3 We will compare different layer-by-layer coatings for sustained release
1.2.2 Outline of the dissertation
This dissertation is arranged into eight chapters Chapter 1 provides an
introduction to the dissertation by describing the motivation and purpose of the study as
well as the outline of the dissertation Chapter 2 is the literature review, m which we
will discuss nanoscale drug delivery systems m general and compare different types of
existing nanoscale drug delivery systems This is followed by a short introduction to the
layer-by-layer self-assembly coating drug delivery system In Chapter 3, we mtroduc
the material, instruments, and general methods that were used in this research Chapter
4 is focused on the top down approach which breaks down big drug particles into nano
size particles Chapter 5 will show a different bottom up approach which forms nano
crystals from solution using ultrasound Chapter 6 will optimize particle size by
changing various parameters, like somcation time and concentration Chapter 7 will
study the release profile of different nano drug particles The main accomplishments of
the dissertation work are summarized in Chapter 8, with directions for further research

CHAPTER 2
NANOSCALE DRUG DELIVERY SYSTEM
2.1 Nanoscale Drug Delivery System
With the application of nanotechnologies to medicine, a new branch of
nanotechnology, called nanomedicine, has been rapidly developed [2] Nanoscale drug
delivery systems use nanosize drug carriers to deliver drugs to the desired sites And
often use active or passive targeting strategies to increase local concentration at the
tumor tissue [3]
Goals of a nanoscale drug delivery system include
1 Improved solubility To increase the drug bioavailability
2 Targeting To increase the local concentration of the drug at desired sites
3 Adjustable rate of drug release To maintain a constant dose at the action site
4 Reduced drug clearances To increase the drug half-life
5 Enhanced stability To reduce drug degradation dunng storage
6 Drug delivery across biobarners like the blood-brain barrier (BBB)
The goals of the drug delivery system were to deliver the conjugated or bound
drug-carrier complex to the selected target and maximize act at desired cancer sites
Controlled delivery of the drug molecules using carrier materials are based on two types
of strategies active and passive targeting Although the former has very sophisticated
strategies, its practical use still suffers from many technical difficulties The latter is

3
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more practical, and there are already many formulations based on "enhanced
permeability and retention effect" [4, 5], which has been the most representative
passive-targeting strategy to bring drug molecules to tumors
The active targeting strategy of the drug nanocarrier was to use a hgand,
attached on the nanocarrier, specific for the receptor of the target tissue

Passive

targeting strategy of the drug nanocarrier was to use the enhanced permeation and
retention (EPR) effect of the cancer tissue Tumor and inflamed tissue tend to have
excessively leaky microvasculature, compared to normal endothelium, which allows the
drug nanocarrier to diffuse through and accumulate at site Especially for cancer tissue,
overexpression

of vascular endothelial

growth factor

will increase

vascular

permeabhhty and let to complicated tumor-vessel architecture Transvasation of durg
carrier takes place either via transcytosis, where by macromolecules are internalized
from the blood at points of invagination of the cell membrane, or paracellularly, via
diffusion through the tight junctions of endothelial cells In combination, these effects
cause enhanced permeation and retention (EPR), resulting m high local drug
concentrations
For nanoscale drug delivery systems, biocompatibihty and biodegradability have
always been considered as one of the most important propenties The unloaded carrier
should be able to biodegrade or metabolize into nontoxic components and cleared
through the circulation system Some studies suggested nanoparticles are cleared
according to size Small particles (<30 nm) are rapidly cleared by renal excretion
Nanocarriers >30 nm are cleared by the mononuclear phagocytic system, consisting of
macrophages located m the liver (Kupffer cells) and the spleen [6], which act as
phagocytotic scavengers Clearance is also dependent on the endothelial fenestral pore

size [6] Fenestral pore size values are highly variable for different patients Clearance
rate of patient could be effect by sex, age and genetics factors It is difficult to
determine the efficiency and toxicity of nanomedicines m different individuals Whether
nanocarriers are taken up by macrophages depends on opsomzation by the innate
immune system [7] Molecules that bind to foreign materials and enhance phagocytosis,
include IgG and IgA antibodies, the complement cascade system and mannose-binding
lectin [8] Therefore, the surface properties of nanocarriers can significantly affect the
rate of clearance by the MPS A useful method for evading opsomzation of large narrow
carriers was developed at Rutgers University [9] in a process call PEGylation, a
polymer, poly(ethylene glycol) (PEG, [CH2CH20]n), is conjugated to the drug carrier
preventing drug particles aggregation and precipitation
Overall, the use of hgand binding nanodrugcarner will improve the drug
therapeutic index according to Equation (1)
_,
,
Maximum non - toxic dose
Therapeutic index =
Minimum effective dose

ngq 1)

The high specificity and selectivity of the hgand on nanodrugcarner increases
the amount of drug delivered to the cancer tissue and decreases the amount of drug at
unwanted sites Therefore, a less systemic drug dose needs to be admimstered to
guarantee an effective concentration at the site of action, and the mimmum efficacious
dose is also lower In addition, because less drug is present at unwanted sites, the
maximum non-toxic dose is higher The overall effect is a sigmficant decrease in
toxicity and adverse side effects

6

2.2 Current Nanoscale Drug Delivery System
Nanoscale drug delivery systems can use different kind of nanoparticles as
carriers In this section we will review some of the most common category of
nanoparticles can be used as drug delivery systems Figure 2-1 shows the structure
schematics of these nanoparticles

Therapeutic agent

Targeting agent

Figure 2-1 Classification of nanoscale drug delivery System
a) drug conjugate, b) dendnmer, c) micelle,
d) microemulsion, e) vesicle, f) core-shell nanoparticle,
g) nanotube

2 2 1 Drug complex and conjugate
Drug complexes and conjugates do not have a defined structure like micelle or
vesicle Drug complexes depend on reversible interactions between carrier and drug

7

Drug conjugates use covalent bonds to join carrier and drug together [10] Drug
conjugates can be prepared using chemical reactions of functional groups between the
drug and the earner molecular There are two major categones of drug complexes and
conjugates one is protein and peptide associated and the other is polymer associated
Proteins and peptides can be used to form nano structures in vanous ways, including
complexation An example of protein associated drug complex nanoparticle for clinical
use is Abraxane™ Abraxane

is an albumin-bound form of pachtaxel with a mean

particle size of approximately 130 nanometers Pachtaxel exists in the albumin-bound
particles in a non-crystalline form Abraxane™ is formed by dissolving pachtaxel in
water immiscible methylene chloride, and adding this to a solution of human serum
albumin in water with low-speed homogemzation This process creates an emulsion
with albumin located at the aqueous-solvent interface

Subsequent high-pressure

homogemzation reduces the particle size and breaks and reforms the disulfide bonds,
essentially crosshnking the albumin coating and stabilizing the particle An evaporation
step volatilizes the methylene chlonde, leaving an aqueous suspension of 140-160 nm
nanoparticles, consisting of an amorphous pachtaxel core sunounded by a 25 nm
coating of albumin with bound pachtaxel Because of its size this matenal can be sterile
filtered [11, 12] Abraxane7 does not contain the problematic solvent - Cremophor EL,
which outperformed conventional pachtaxel at an equitoxic dose while decreasing
toxicity, due to longer circulation time and lower off-target activity [13, 14]
Supramolecular complexes between host and guest molecules are also considered as
useful for the drug administration Cyclodextrms are natural products and can entrap
entire or part of guest drugs in their inside cavity in a specific mode Chemical
modification of natural cyclodextrms molecular could improve their efficacy by altenng

8
their solubility or capacity for the guest drugs Cyclodextrms are regarded as useful
additive in drug delivery systems [15, 16]
2.2.2 Dendnmer
Polymenc dendnmer is a kind of hyperbranched nanostructures

One of

dendnmers' advantages is that its size can be controlled by adjusting the number of
polymenzation generations Dunng the polymerization progcess, monomer molecules
joined into a sphencal nanostructure Inside this dendnmer nanostructure are cavities
which allowed therapeutic agents to be loaded with great loading efficiency [17]
The polymenzation progresses of dendnmers can be precisely controlled to
obtain the desired final product The molecular weight, chemical composition, and
nanostructure of the final product can be precisely designed [18] With controlled
polymer structure and narrow polydispersity, dendnmers may be ideal platforms for
drug delivery system An example of dendnmers for clinical usage is VivaGel ™ It is
currently on tnal for safety and efficacy as a microbicide
2.2.3 Micelles
Micelles are one of the simplest molecular assemblies and can carry
hydrophobic drugs in their central core or m their palisade layer [19] Micelles
nanoparticles are interesting structures for earners of drugs because they can form
relatively uniform size structures Micelles can be formed using a variety of amphiphihc
materials as outside coating and using hydrophobic drug as central core, and can
incorporate multiple functionalities into a single structure Unfortunately, surfactants
used to form micelles often have toxic effects on human bodies Only a few kinds of
surfactant are approved by FDA for drug solubilization Additional use of organic
solvents may increase drug solubility but disturbs micelle formation in some cases [20,

9
21 ] Lacking an aqueous core, the drug must be bound to the polymer before micelles
formation Drug needs to be conjugated to an anchor polymer molecule, or entrapped
and bonded inside the hydrophobic core of the micelle [22] Micellar structures,
including polymenc micelles, have been extensively studied as drug earners [23]
Polymeric micelles made of hydrophihc-hydrophobic block copolymers are used as
drug earners [34] which can be concentrated in the tumor tissue based on the EPR effect
[25], and may be used for gene therapy as well [26] Because hydrophihc-hydrophobic
block copolymers' cntical micelle concentrations are much lower than those for lowmolecular-weight surfactants, they have higher stability and lower toxicity

The

hydrophobic portion of the copolymer forms the micellar core The hydrophihc block of
the copolymer forms the micellar corona This corona (commonly consisting of PEG,
HPMA, or other hydrophihc polymers) confers these micelles with biocompatibihty,
stealth-like properties, and a platform for functionahzation [27-29] Genexol-PM

is a

formulation of pachtaxel encapsulated in a polymenc micelle formed by the solid
dispersion technique from the biodegradable block copolymer, monomethoxy
poly(ethylene glycol)-block-poly(D,L-lactide) [30] Several climcal trials have already
been carried out evaluating the safety and efficacy of Genexol-PM™ m metastatic
breast cancer, solid tumors, and non-small-cell lung cancer [31-33]
2.2 4 Microemulsion
Entrapment of drugs within emulsions [34] results in vanous improvements in
the performance of the drugs including suppression of side effects, prolonged drug
retention in blood circulation, and enhanced drug efficacy at the target site based on the
EPR effect Lipid emulsions have a long history m the pharmaceutical practice as
nutnents, commercialized emulsion formulation was achieved relatively easily by
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incorporating hydrophobic drugs, such as steroids, into the traditional emulsions
Microemulsion is an equilibrated solution, unlike emulsions, and it is utilized for oral
formulations [35-37] Formulations containing surfactants, drugs, and oils, which were
designed to spontaneously form microemulsions upon contact with water in the stomach
and small intestine, induce reproducible drug release This formulation offers great
contribution to organ transplantation [38], since it requires precise control of the
immunosuppressant concentration in plasma Microspheres composed of appropnate
polymers, such as biodegradable polymers, enable prolonged drug-release after
intravenous injection Administration frequency has decreased from daily to monthly by
using this earner [39]
2.2.5 Vesicles
Vesicular structures have been extensively studied as drug delivery system The
two major categories of vesicles are liposomes and polymer vesicles Vesicles have the
capacity for encapsulation of hydrophobic or hydrophihc drugs Vesicles can be design
to use covalent or non-covalent bonds to load drugs Liposomes, (or lipid vesicles) [40]
can be used to load hydrophihc drugs into an intenor aqueous phase Liposomes can
also be used to load hydrophobic drug lipid phase in the shell Liposomes are
considered to be ideal drug earners, because of their surface characteristics can be
altered easily and their size is controllable Use of liposomes as a climcal drug delivery
system still need to face some technical difficulties like mass production, storage
stabilities, and lack of efficacy after accumulating a the target site Recently, liposomes
have also been studied as non-virus vectors for gene therapy [41]

Liposome

formulations for drug delivery have been in development for almost half a century, and
have produced climcally successful applications [42] Polymenc vesicle structures, or
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polymersomes, have been described more recently, and have unique potential as drug
earners An example of the climcal vesicle formulation is Doxil ™, also known as
liposomal Dox Encapsulation of Doxorubicin in liposomes shielded by polyethylene
glycol (PEG) prolongs systemic drug circulation, improves safety, and increase the
therapeutic index relative to free Doxorubicin [44,45]
2.2.6 Core-shell nanoparticles
Core-shell structured nanoparticles consist of an inner nanoparticle core and a
hydrophihc shell The inner nanoparticle core could be made with a wide vanety of
matenals including Quantum-dots, metals, metal oxides, and polymers among other
materials The core is sunounded by a hydrophihc shell usually using covalent or lomc
bonds or electrostatic force
One category of core-shell nanoparticles has been developed during the
chemical modification of gold and other materials nanoparticles to increase their
physiological stability and control drug association and release [46] These core-shell
nanoparticles offer stability and modifiable surface properties, and can even produce
contrast depending on their composition, size, and shape [47, 48] These core-shell
structured nanoparticles make for a very robust drug delivery vehicle due to the vast
variety of elements that can be used as the core and shell components Despite the
advantages already mentioned, these core-shell nanoparticles suffer from some inherent
shortcomings, such as biotoxicity, rapid clearance rate, and poor biodistnbution and
biodegradation Various strategies are in development to circumvent these problems
[49, 50]
Another category of core-shell nanoparticles uses porous materials as an inner
core to cany drug Porous matenals with large surface area and pore volume are
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regarded as good candidates for drug storage and delivery As a example, mesoporous
silica have been investigated as a drug earner materials because of its mesochannels,
which have defined diameters in the ranges of nanometers to tens of nanometers provide
reliable nanospaces for drug accommodations [51, 52] In addition, their huge pore
volume per unit mass of matenals enables us to entrap large amounts of drugs In some
pioneenng approaches, the inlets of channels are modified to add gate functions,
resulting in controlled release by external stimuli [51-53] Not limited to mesoporous
silica, mesoporous carbon and related matenals [54, 55], biocompatible porous calcium
phosphate [56], and metal-organic frameworks (MOF) [57] have also been paid
attention as future strong candidates for drug delivery applications
2.2 7 Nanotubes
Carbon nanotubes are used as drug earners because of their nanocavities and
high surface area [58, 59] However, there is much concern regarding the long-term
toxicity of the nanotubes in practical uses due to their geometrical similarity to asbestos
[60] Carbon nanohorns may be a better candidate for drug earner [61] due to theirs
lower aspect ratio, which is considered to play important role in the toxicity Carbon
nanotubes (CNTs) are cyhndncal tubes composed solely of carbon and can be formed
either as single-walled or multi-walled, for more stability [62] These CNTs are being
investigated as therapeutic nanoparticles because of their tunable properties and ability
to incorporate multiple functionalities Amine-functionahzed, single-walled CNTs were
conjugated by amide-linking to a cisplatm-fohc acid derivative as targeted delivery
system, has show better performence than a conventional cisplatin formulation [63]
Another study conducted by Rushng et al used carboxylated single-walled
CNTs conjugated with cisplatin and epidermal growth factor to target cancer cells
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which have overexpress of the epidermal growth factor receptor The targeted CNTcisplatin conjugate improved the selective killing of the targeted tumor cells [64] Many
studies have reported CNTs to be effective earners of therapeutics and imaging agents
in vitro, however, in vivo studies have lead to concerns regarding the associated
toxicities [65-67]
An interesting development was recently reported on drug delivery with
halloysite clay nanotubes [68-71] These clay nanotubes have a larger diameter than
carbon nanotubes (ca 50 nm external diameter, 15 nm lumen diameter and length of ca
800 nm), and they are biocompatible [72] Drugs may be loaded into these tubes within
a minute at ca 10-20 wt % and then slowly released over 10-50 hours [69] It is not
assumed that it would be possible to inject halloysite clay nanotubes into the blood
stream, due to their inorganic composition, but their applications for dermatological
(including rectal), cosmetic and dental delivery were considered as well as
incorporation into bone and tooth implants

2.3 Layer-by-layer Coated Nanoparticles for Drug Delivery
2.3.1 Outline of LbL assembly
Before we discuss the LbL capsules for drug delivery we will first briefly review
the layer by layer self assembly technique in this section [73, 74] Self-assembly of the
nano particles using electrostatic interactions through a layer-by-layer process, was first
proposed by R K Her [75] The idea was developed and first realized by Decher,
Mohwald, Lvov, et al [76, 77] Because the self assembling mechanism is so simple, the
requirements for the apparatus necessary for the process are very low (requiring only
beakers and tweezers) [78], and the procedures are easy to perform, this methodology
was quickly adapted by many research groups with the utilization of layer by layer
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assemblies of various materials including synthetic polymers [79-80], biomaterials [8184], inorganic materials [85-87], and supra-molecular assemblies [88-90] Relatively
high concentrations of the charged substances in the solution results in excess
adsorption of the substances The surface charge was first neutralized and then
resaturated lead to charge reversal (Figure 2-2) Reversing of the surface charge makes
a continuous assembly between positively and negatively charged matenals The
driving forces for the LbL self-assemblies are not limited to electrostatic interactions
Many kinds of interactions , such as metal coordination [91, 92], hydrogen bonding [93,
94], covalent bonding [95, 96], supramolecular inclusion [97], bio-specific recognition
[98, 99], charge transfer complex formation [100], and stereo-complex formation [101,
102] were reported and could be used in the LbL process Many other deposition
techniques including spin-coating [103, 104] and spraying [105], were used for the LbL
assembly Also automatic machines were developed for the LbL assembly [106, 107]
The matenals used for LbL assembly also have been widely tested In the 90's, most
researchers used synthetic polyelectrolytes, such as PAH, PEI, PDDA, PSS and PAA,
but cunent research, especially related to biomaterials and pharmacology, uses natural
biodegradable polyelectrolytes, including positively charged chitosan, dextran amine,
gelatin A, protomme sulfate, and negatively charged chondroitin sulfate, dextran
sulfate, hyaluronic acid, hepann, gelatin B and sodium alginate
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Figure 2-2 LbL assembly process outline

The LbL assembly techniques are considered suitable for biomaterials, because
the process is simple and is performed m mild environment The LbL assembly is
usually performed at room temperature in a pH neutral aqueous solution Because the
LbL technique does not require special conditions like high temperature or extreme pH,
biomaterials can be assembled under favorable conditions Another advantage of the
LbL assemblies for biomaterials is the porous nature Unlike Langmuir-Blodgett (LB)
films, LbL films allow diffusion of matenals Activities of the enzyme glucose oxidase
were reported to be blocked after covering with only a few layers of lipid LB films
[108, 109] The LbL films with a single component enzyme (glucose oxidase) or
multiple enzymes (glucose oxidase and glucoamylase) do not have a senous decrease in
enzyme activity after an increase m the numbers of layers [110, 111] These facts show
that LbL films allow the diffusion of materials This ability is a crucial factor in drug
delivery functions Additionally, it was also reported that biomaterials embedded withm
the LbL films show better stabilities [112]
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An important development in the LbL technique was applying LbL technique to
assembly on colloidal particles [113] This technique was first developed by G
Sukhorukov, E Donath, F Caruso, and H Mohwald in the Max Planck Institute for
Colloids and Interfaces [113-122], and then was quickly adapted by other groups
Instead of using conventional flat surface supports, LbL films were assembled
sequentially on a colloidal core Subsequent destruction of the central colloid particle
core could lead to hollow shells A typical example of preparing functional hollow
shells is shown in Figure 2-3 where DNA molecules, retaining the natural double-helix
structure, were encapsulated inside a biocompatible polyelectrolyte microshell [123,
124] In the first step, MnC03 particles were used as template, cores were suspended in
a DNA solution, and the addition of spermidine solution into stmed MnC03/DNA
solution caused precipitation of a water-insoluble DNA/spermidine complex onto the
MnC03 particle

Then in the second step, LbL assemblies of biocompatible

polyargimne and chondroitin sulfate on the complex core were conducted In the third
step, dissolution of the MnC03 template particles resulted in biocompatible shells
contaimng a DNA/spermidine complex In addition, further decomposition of the
DNA/spermidine complex led to a selective release of low molecular weight spermidine
to complete the DNA entrapment In another example, De Smedt and coworkers
reported a labeling system for LbL drug delivery using the barcode concept with
encoded fluorescent polystyrene with captured antibodies [124]
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Figure 2-3 Preparation of functional hollow shells

2 3.2 Recent progress of LbL microshells in drug delivery functions
The LbL microshells could be used in many applications including in life
science [125-127] The LbL microsells used as drug earners have been attracting a lot
of attention Most LbL shells used in these applications have diameter at micrometer
range Raichur et al reported encapsulation and release profiles of rifampicin, an
antituberculosis drug, using hydrogen-bond assembly LbL microshells of poly(vinyl
pynohdone) and poly(methacryhc acid) [128] Release profiles showed a burst release
Above pH 7, the maximum release rate was achieved because the microshells rapidly
disintegrate The nfampicm released from the LbL microshells shows the same efficacy
as the free drug This result indicates the drug properties have not changed because of
possible disturbances during the encapsulation and release process Zhao, et al reported
the loading of doxorubicin, an anti-tumor drug, into preformed LbL microshells The
doxorubicin loaded LbL microsells' effect in tumor treatment was assayed by in vitro
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cell culture tests and in vivo animal experiments [129] The LbL microshells contain
negatively charged carboxylmethyl cellulose which entraps levels of the positively
charged doxorubicin ten to a hundred times higher than the feeding concentration The
encapsulated doxorubicin can effectively trigger the apoptosis of HepG2 tumor cells on
in vitro tests The result shows that the LbL microshells have the ability for drug
delivery and cancer treatment on an animal expenmental level Chen, et al encapsulated
another anti-cancer drug artemisinin in the crystal form with LbL microshell containing
chitosan, gelatin, and alginate using LbL technique [130] The release rate of
artemisinin could be adjusted by various parameters, such as polyelectrolyte types,
number of polyelectrolyte layers, sodium chloride concentration, and ethanol
concentration in the polyelectrolyte solution
Many researchers also try to control of drug release using external stimulaton
Zhang, Gu, et al synthesized alginate-templated magnetically sensitive LbL microshells
[131] When a high-frequency magnetic field was applied, doxorubicin's drug release
rate from the microshells was significantly increased

The doxorubicin-loaded

microshells showed much lower cytotoxicity at the high drug concentration in
comparison with doxorubicin

Choi et al prepared LbL microshells containing

photoacid generators, which made them UV sensitive [132] UV light will induce
activation of photoacid generators and lead to the release of protons The decrease in the
pH of the solution tnggered the swelling of the LbL microshells Thus, opemng and
closure of the LbL microsell was achieved by exposure to UV light and washing with
pH neutral water In addition, prolonged UV light exposure led to the breakage of the
LbL microshells, which results in rapid release of the entrapped drugs
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Protein delivery using LbL shells is also an active area in cunent research
Zhang, Li, et al reported encapsulation and controlled release of protein using
biodegradable LbL microshells The microshells consisted of dextran sulfate and
chitosan Bovine serum albumin (BSA) was used as the model protein BSA was
encapsulated in the LbL shells [133] The cell viability test indicated that the LbL
microshells had good biocompatibihty De Geest, Parak, et al encapsulated with a
model of a nonactive prodrug, a self-quenched fluorescence-labeled protein in
biodegradable LbL microshells [134] After the microshells uptake by living cells, the
walls of the microshells were degraded and digested by intracellular proteases Wall
degradation allowed intracellular proteases to reach the protein loaded inside of the
microshells Enzymatic fragmentation of the fluorescence-labeled protein leads to
individual fluorescence-labeled peptides So, only prodrugs inside the microshells that
reach into the cells are the only ones activated, and those in shells in the extracellular
environment cannot be activated Akashi et al reported entrapped proteins inside
biodegradable microshells via LbL assembly Chitosan and dextran sulfate were
assembled onto a protein-entrapping mesoporous silica particles, and then the silica was
subsequent dissolved [135] Sustained release of the encapsulated proteins was achieved
by using the enzyme to degrade the hollow shells
Variously specifically designed polymers have been used to compose the LbL
microshells For example, Vancso et al developed organometalhc polyelectrolyte
multilayer microshells, which are composed of polyanions and polycations of
poly(ferrocenylsilane) (Figure 2-4) [136] Poly(fenocenylsilane) have redox-active
fenocene units in the main chain, which makes the shell wall permeability sensitive to
the redox state In fact, the permeability of these microshells can be tuned using
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chemical oxidation, resulting in a fast shell expansion accompanied by a significant
permeability increase in response to a very small trigger

Figure 2-4 Organometalhc polyelectrolyte multilayer microshells,
composed of polyanions and polycations of
poly(fenocenylsilane)

Caruso et al developed a new type of polymer hydrogel LbL microshells based
on disulfide cross-linked poly(methacryhc acid) and poly(vmylpynohdone) The
disulfide cross-linking is sensitive to redox state It can act as redox-active tngger for
shell degradation [137] They also developed degradable LbL microshells as drug
earners for the delivery of oligopeptide antigens to antigen presenting cells (Figure 2-5)
[138] Oligopeptide sequences were first covalently linked to a negatively charged
polymer via biodegradable linkages Then this conjugate was adsorbed onto amine-
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functionahzed silica particles The peptide-coated particle was coated with thiolated
poly(methacryhc acid)

(PMASH)

and poly(vinylpynohdone) (PVPON) Dissolving of

the silica core and disruption of the hydrogen bonding between polymers resulted in
disulfide-stabihzed microshells Glutathione, a natural reducing agent, can be used to
cut the disulfide bonds which causes release of the peptide from the microshells

Figure 2-5 Degradable polymer microshells as earners for the
delivery of oligopeptide antigens

Many researchers combine of the LbL technique with other molecular assembly
technique, such as liposomes or micelles, together to create various shell systems
Addison et al develpoed LbL microshells constructed entirely from a cationic/
zwitteriomc pair of pH-responsive block copolymer micelles [139] Layers of aniomc
poly[2-(dimefhylamino)efhyl

methacrylate-hlock-poly(2-(diethylamino)ethyl

crylate)] and cationic poly(2-(diethylamino)ethyl)

metha-

methacrylate-block-poly(meth-
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acrylic acid) copolymer micelles were alternately assembled onto CaC03 colloidal
templates Then add in dilute ethylenediaminetetraacetic acid solution to dissolve the
CaC03 core and form hollow polymer microshells This type of LbL microshells is
composed entirely by pH sensitive block-copolymer has potential application for the
encapsulation and tnggered release of drugs Li, Hu, et al fabncated via a layer-bylayer technique, templated on CaC03 particles with built-in polymeric micelles based
on polystyrene-b-poly(acryhc acid) [140] This type of LbL microshell can selectively
entrap positively charged substances such as rhodamine B and lysozymecan The
positively charged substances can be entrapped in the shells where the concentration is
much higher than that in the incubation solution The encapsulated compounds shown
sustain released to a certain degree, as suggested by in vitro release experiments Caruso
et al reported using micelles for LbL assembly They synthesis DNA-grafted poly(Nlsopropylacrylamide) (PNIPAM) micelles, then assembly PNIPAM micelles into LbL
films, and then use poly(ethylene glycol) (PEG) to functionahze the DNA-PNIPAM
microcapsules [141] The combination of hydrophobic core and alkyne "click" groups,
along with the biodegradabihty of DNA, offers a multifunctional and versatile
DNA-polymer capsule system that can be used for the controlled delivery of
therapeutics
Fukui and Fujimoto combined the liposome preparation and the LbL deposition
together to prepare hollow shell structures [142] Chitosan was deposited onto a
negatively charged liposome surface and form a cationic polymeric layer Then dextran
sulfate or deoxyribonucleic acid was used to form an aniomc polymers layer They
reported that chemical substances with different charges, alendronate, pyranine, and
glucose, were encapsulated into microshells where the release rate was suppressed by
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the polymer shell wall inespective of charges [142] Also they use DNA denaturation as
a temperature dependent switch to achieve the temperature-dependent release Tabnzian
et al developed a delivery system for bone growth factors consisting of a liposome core
incorporated into a shell of LbL-assembled natural polyelectrolytes [143] The prepared
hydrophihc, monodisperse, spherical and stable cationic nanoparticles (< or =350 nm),
as a delivery system, localized the effect of the released bone growth factors within the
site of injection in muscle Ramaye et al developed a combination of magnetic
liposomes and LbL assembling techniques [144] Superparamagnetic nanoparticles were
encapsulated in liposomes prior to the stepwise adsorption of LbL assembly Magnetic
field also allows a fast separation of coated liposomes from unbound polyelectrolytes
The presence of magnetic nanoparticles and the polyelectrolyte shell opens allows to
use external magnetic field to manipulate and target drug earners
Integrated shell structures have also been proposed De Smedt et al designed
self-exploding gel beads that can release micrometer-sized shells at the time of
explosion (Figure 2-6) [145] The larger gel beads were loaded with small LbL
microshells When the polyelectrolyte coated gel beads explode under alkaline
conditions, through rapid hydrolysis of the carbonate esters connecting the polymerized
methacrylate groups with the dextran backbone, the smaller LbL microshells become
suddenly released

Self-exploding gel beads releasing antigen containing LbL

microshells at different times after injection could become promising materials for
vaccination purposes The reverse-phase was used to coat polymer layers onto agarose
microbeads contaimng tns-buffer for the formation of LbL shell-walls onto the
microbeads The polymer-coated agarose microbeads were transfened from an organic
to an aqueous solvent where the tns-molecules induced an osmotic pressure in the
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microshells' interior The inflation of the LbL microshells caused the expansion of the
LbL shell-walls The inflated microshells can control localized chemical or enzymatic
reactions that are useful in biomedical applications Ke, et al developed a bi-mode
ultrasound/fluorescent imaging agent through LbL assembly of poly(allylamme
hydrochlonde) (PAH) and CdTe quantum dots onto microbubbles produced by
somcation of a mixture of Span 60 and Tween 80 [147] The Quantum-dot-modified
microbubbles not only maintained the ability of ultrasound imaging, but also could used
as a targeted-drug controlled-release system to deliver the quantum dots by ultrasound
targeted microbubble destruction

Small LbL Shell

I

LbL Shell
Figure 2-6 Self-exploding polyelectrolyte coated gel beads
releasing micrometer-sized shells at the time of
explosion
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In conclusion for Chapter 2, layer-by-layer (LbL) nanoassembly is a simple
method allowing the design of multilayer architectures with nanometer precisions

It is

based on the alternate re-saturated adsorption of oppositely charged components, such
as synthetic and natural polyelectrolytes, proteins and nanoparticles The only rule of
thumb is sequential adsorption of positively and negatively charged components
resulting in any pre-determmed composition multilayer film

One forms films

consisting of bilayers of electrostatically bound cationic and anionic macromolecules,
and the typical bilayer thickness is one to a few nanometers Following the first LbL
papers published in the beginning of the mneties by G Decher, H Mohwald, Y Lvov,
M Rubner and others, one can find around 8,000 publications dealing with the LbL
technique It is interesting that until the last few years, the majority of these works were
devoted to LbL assembly predominantly using sodium poly(styrene sulfonate) - PSS,
poly(allylamine) hydrochlonde-PAH and poly(ethyleneimine)-PEI These PSS, PAH,
and PEI multilayers are the most studied, but, in recent years, researchers began using
natural polyelectrolytes and proteins Now, one can conclude that the LbL method
works perfectly for the assembly of aniomc compounds, such as alginic acid, hyaluronic
acid,

chondroitin

sulfate,

heparin,

dextran

polyanunoacids, DNA, and catiomc ones

sulfate,

carboxymethyl

cellulose,

chitosan, dextran amine, polylysine,

collagens, protamine sulfate, gelatin A, and others Therefore, we have a group of
biocompatible and biodegradable materials (in many cases FDA approved) and the
LbL-techmque to assemble them in a controllable manner in multilayers of 2-500 nm
thickness
How can these architectural multilayers be used for drug delivery*? An answer is
by formation of microcapsules loaded with drugs Formation of LbL multilayers on tiny
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templates and performing LbL encapsulation was first introduced in 1999 in Max
Planck Institute, Germany by G Sukhorukov, E Donath, F Caruso, H Mohwald and Y
Lvov Generally, LbL encapsulation is the same method as described above for a planar
substrate but applied to small 2-5 micrometer diameter drug particles or sacrificed
polymeric, MgC03, CaC03 or silica cores The possibility to design any thickness or
composition of such LbL shells allowed control of drug diffusion from the capsules For
different drugs, the vanation of the capsule wall thickness within 20-100 nm allowed
release time from 10 mm to 5 hours This is the mam idea for LbL encapsulation for
controlled drug delivery
Cunently, one can indicate two methods in LbL encapsulation 1) The more
common approach for formation of LbL microcapsules on sacnficed cores, dissolution
of such cores and loading empty LbL microshells with drugs or proteins through a pH
dependable capsule wall pore opemng In this case, drug loadmg is 5-10 % The
following drugs were analyzed for LbL encapsulation

lbuprofen,

furosemide,

nifedipine, naproxen, biotin, vitamin K3, insulin, dexamethasone, tamoxifen, pachtaxel
2) The second direction is much less known (only four publications exist from LaTech's
group) using the LbL nanoencapsulation of low soluble drug nanoparticles (which
allowed ca 70-80 % drug loading)
Therefore, in LbL capsules one can see two tendencies Making microcapsules
with sophisticated multifunctional shells of contaimng 5-10 wt % of drugs and having
the ability for switchable release with few to tens of hours In most of the recent
published papers, such LbL capsules have a diameter of a few micrometers It appears
to be too large for blood injection but these LbL microcapsules have a very thin flexible
wall and they have a certain ability to squeeze through nanow capillaries similar to

27

blood cells

Another tendency is making very thin LbL-shells (two-three

polyelectrolyte layers of 5-10 nm) on 100-200 nm diameter cores of low soluble drugs
(often anti-cancer drugs) In this encapsulation, LbL coating provides a strong surface
charge producing stable nanocoUoids of initially poorly soluble matenals

It is this

second approach for low solubility cancer drug nanoformulations that will be further
developed in this dissertation

CHAPTER 3
INSTRUMENTATION AND MATERIALS
LbL assembly was earned out using polyallylamine hydrochloride (PAH),
polyethylemeimine (PEI), protamine sulfate and chitosan, as positively charged
polyelectrolytes and bovine serum albumin (BSA), algimc acid, and sodium polystyrene
sulphonate (PSS), as negatively charged polyelectrolytes (used at concentration of 2
mg/mL) All polyelectrolytes and albumin were purchased from Sigma-Aldnch except
pachtaxel is purchased from LC Laboratones Inc (Woburn, MA), curcumin is provided
by Sabmsa Corporation (East Windsor NJ) Deiomzed water and phosphate buffered
saline (PBS) buffer were used at pH 7 2

Ultrasonicator UlPlOOOhd (Heilscher,

Germany) with titanium sonotron was used at a power of 15 W/cm

During the

experiments, the temperature was controlled at 25-30 °C
Surface potential (zeta potential) and particle size measurements (by light
scattering)

were performed

using

ZetaPlus

microelectrophoresis

(Brookhaven

Instruments, Co ) Additionally, we used Precision detectors PDExpert light scattenng
Workstation to check the radius of gyration of our drug nanoparticles A field emission
scanning electron microscope (Hitachi S 4800) was used for particle imaging XRD
experiments were performed with the help of a Bruker D8 Discover X-ray Diffractometer to determine the crystalline structure of drug nanoparticles
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The drug release rates of nanocapsules with different shell composition were
measured using standard 1 mL horizontal diffusion chambers with 0 2 um cellulose
acetate membranes The drug dispersion was placed to the side of the diffusion chamber
contaimng a magnetic stmer and the drug was released against the same volume of
PBS, pH 7 2 to mimic the sink conditions expected in vivo The concentration of
released drugs in PBS was dissolved in ethanol at 1 1 (v/v), centnfuged to remove
insoluble polyelectrolytes and measured with a UV spectrophotometer (Agilent 8453
Wavelength range 190-1100 nm) Curcumin was measured at 490 nm, and pachtaxel
was measured at 245 nm Also the same measurements were done to calculate product
yield at the end of somcation Further, we describe the instruments used in this work in
more detail

3 1 Ultrasonicator
A Hielscher UlPlOOOhd ultrasonic processor, Figure 3-1, was used to prepare
nanoparticles in this research
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Figure 3-1 Hielscher UlPlOOOhd ultrasomc processor

When ultrasomc energy is applied to liquids, and if amplitude and acceleration
are high enough, the phenomenon of cavitation occurs The cross-section of sonotnn
used conesponded to the surface area of the drug dispersion to maximize
ultrasonication power The liquid bursts and vacuum bubbles are generated during the
alternating high-pressure and low-pressure cycles When these small bubbles cannot
absorb more energy, they implode during a high-pressure cycle, so pressures up to
1,000 bar and shock waves as well as liquid jets of up to 400 km/h are reached locally
These intense forces, caused by ultrasonic cavitation, take effect on the enclosing
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droplets and particles The main objective of power ultrasonics consists of cavitational
forces, with heating being mostly a welcome side-effect Cavitation and the effects
descnbed above cause mterparticle collision

3.2 Zeta Potential Analyzer
A ZetaPlus zeta potential analyzer (Brookhaven Instruments, Co ), Figure 3-2,
was used to measure the surface charge of nanoparticles dunng the LbL assembly
process This instrument also can be used to measure the particles hydrodynamic
diameter using light scattering
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Figure 3-2 Zeta potential analyzer by Brookhaven Instruments, Co.

Zeta potential meassurement was calibrated using a BI-ZR3 zeta potential
reference material provided by Brookhaven Instruments, Co.
100 mg of BI-ZR3 was added to 20 mL of the 1 mM KC1, result in 5mg/mL
concentrate. Then the concentrate dilutes to 1.25X102 mg/mL. This standard sample is
used to have a mean zeta potential value of 53 mv ± 4 mv, and 300 nm mean size.
Zeta potential is used as a surrogate for surface change and is often measured by
observing the oscillations in signals that result from light scattered by particles located
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in an electnc field, though there are other approaches There are a number of
instrumental configurations by which this is achieved, mostly using a doppler shift, and
the users should familiarize themselves with the particular approach implemented in
their equipment Instrumentation concerns aside, the need for dilution begs the question
of what is an appropnate diluents, because its choice can profoundly influence the
surface chemistry and thus the results This analyzer was calibrated using a BI-ZR3
reference matenal from Brookhaven Instruments, Co

3.3 Dynamic Light Scattering
The Precision detectors PDExpert light scattering workstation Figure 3-3 is a
multi-detector light scattering platform that can be employed for light scattenng
measurements on a static sample (eg a test tube) or for flow through measurements
(e g high performance liquid chromatography, gel permeation chromatography and size
exclusion chromatography) The workstation is designed to provide the ultimate in
detection for characterization of polymers, nanoparticles, lipids, colloids and proteins
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Figure 3-3 Precision detectors PDExpert light acattering
workstation

DLS, also known as photon correlation spectroscopy (PCS) or quasi-elastic light
scattering (QELS) records the variation in the intensity of scattered light on the
microsecond time scale. This variation results from interference of light scattered by
individual particles under the influence of Brownian motion, and is quantified by
compilation of an autoconelation function. This function is fit to an exponential, or
some combination or modification thereof, with the conesponding decay constants
being related to the diffusion coefficients. Using standard assumptions of spherical size,
low concentration, and known viscosity of the suspending medium, particle size is
calculated from this coefficient. The advantages of the method are the speed of analysis,
lack of required calibration, and sensitivity to submicrometer particles. Drawbacks
include the necessity of significant dilution to avoid artifacts, the need for cleanliness in
sample preparation, the mathematical instability of the procedure used to extract decay
constants, and the possible influence of interparticle interactions. DLS is a stand-by
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method for those working in the area of nanoparticles because of the simple measure

3.4 X-Rav Diffractometer
A Bruker D8 X-Ray diffractometer was used to determine the crystal structure
of the nanoparticles (Figure 3-4)

Figure 3-4 Bruker D8 Discover X-ray diffractometer

3.5 SEM
Figure 3-5 shows the Hitachi SEM which was used for nanoparticles
visualization Diluted drug nanoparticles dispersion was dropped on a suitable substrate
and coated with a ca 0 5 nm gold layer to provide conductivity
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Figure 3-5 Hitachi S-4800 scanning electro microscope

This SEM also has an energy-dispersive X-ray spectroscopy (EDX) detector
(EDAX Sapphire). EDX Analysis can be used to determine the element composition of
the sample.

3.6 Ultra Violet Spectrophotometer
An UV-vis spectrophotometer (Agilent 8453), Figure 3-6, was used to measure
the concentration of drug in the release test. The drug release test measures the
pharmacodynamic diffusion of the nano drug particle in a side-by-side diffusion
chamber.
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Figure 3-6 Agilent 8453 UV-Vis spectrophotometer

CHAPTER 4
DRUG NANOPARTICULATION VIA TOP-DOWN APPROACH
Nanoparticle

drug

earners were

developed

using

a combination

of

ultrasonication and encapsulation with synthetic and biodegradable polyelectrolytes
Two different approaches to attain the desired featured properties are the "top-down"
and "bottom-up" synthetic methods These two methods are desenbed in Chapters 4 and
5 A common feature of these two related methods is ultrasonication-driven formation
of drug nanocores accompanied by a simultaneous polycation coating providing
aqueous colloidal stability The "top-down" method was more efficient in the
preparation of large amounts of 200-250 nm diameter pachtaxel capsules, and the
"bottom-up" approach allowed for the formation of smaller capsules of ca 100 nm
diameter but with less product yield Some sections of these two chapters were
published in papers written by the author of this dissertation and will be
conespondingly refened [148] and [149]

4.1 Methodology
Powerful ultrasound generates micro-bubbles in a liquid These micro-bubbles
collapse in microseconds If any solid particle is near the bubble dunng the collapsing,
jets of fluid and shock waves will hit the particle and break it up While adding
polyelectrolyte into the solution, the typically negative surface of the newly formed
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drug surface will help to keep particles from aggregation Thus, a smaller particle size
can be achieved with a better size distribution Because the ultrasonication process
breaks down the particles, it is a mechanical process The formed particles will have a
wide range of sizes Both power and somcation time effect the nanoparticles' size
distnbution In general, the higher the power and the longer the time, the smaller the
particles will be But if one stops somcation, particles will aggregate To prevent the
aggregation during the somcation and increase the efficiency of the somcation, we
added polycations that adsorbs onto the drug nanoparticles and prevents re-aggregation
The mimmum amount of polycation needed for complete coverage was calculated in
Appendix A The surface zeta potential of the particles changed to positive during the
polycation adsorption and reached of ca + 40mV
For drug encapsulation, anionic sodium polystyrene sulfonate (PSS) of MW 70
KDa and catiomc poly(dimethyldiallyl ammonium chlonde) (PDDA) of MW 100 KDa
were sequentially adsorbed onto the particles of different drugs at pH 6, and then the
desired number of layers in the capsule shell was fabncated

Biodegradable

polyelectrolytes that were used for the LbL assembly are protamine sulfate and
chondroitin sulfate The multilayer shells that are fabncated on the drug help in
prolonging the release of the drug Figure 4-1 shows the scheme for top-down approach
The verification of the alternation of surface charges and particle size were done with a
ZetaPLus Brookheaven microelectrophoretic zeta-potentiometer A visualization of the
fabncated microcapsules was completed using SEM
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Drug crystal
suspand in D) water

The strong Jet flow crash drug
crystal into small pieces
New surface soon covered with
oppositive charged PAH

PAH/PSS or BS/PS
LbL assembly on to particle

Figure 4-1 Scheme for top-down approach

4.2 Curcumin Nanoformulation
Curcumin is a well known natural compound traditionally used as a food
additive or a health nutrient supplement in many oriental countries Recently, its anticancer activity was recognized [150] It is a low soluble compound (the aqueous
solubility is ca 0 01 mg/mL) The curcumin structural formula is shown in Figure 4-2

OH

O

O

Figure 4-2 Structural formula for curcumin
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4.2.1 Preparation of curcumin nanoparticles
The following expenmental step-by-step sequence was used to prepare
nanoparticles of curcumin
1)

10 mg curcumin powder was mixed with 10 ml of DI water

2)

The mixture was pre-somcated for 5 mm to form curcumin suspension

3)

2 mL of 1 5 mg/mL catiomc PAH were added to the suspension

4)

45 mm somcation was applied

5)

The curcumin nanoparticles were washed twice with DI water using
centnfugation at 7000 rpm (5204 g rcf) for 10 min to separated
nanoparticles from supernatant and re-dispersed in 20 mL of DI water

6)

2 mL of 3 mg/mL anionic PSS were added to the mixture, 10 mm of
reaction time was allowed for the polyelectrolyte adsorption

7)

The

supernatant

was removed

by centnfugation

at

7000

rpm

Nanoparticles were washed with DI water and re-dispersed
8)

Steps 6-7 were repeated for next layer of catiomc PAH

9)

Steps 6-8 were repeated several times to achieve the desired number of
polyelectrolyte layers in the coating

Instead of catiomc PAH and anionic PSS, biodegradable polyelectrolytes such
as protamine sulfate (PS), bovine serum albumin (BSA) and chondroitin sulfate (ChS),
may be used for the coating
The alternation of electrophoretic (£) potential demonstrates a step-wise
formation of the LbL-shell consisting of catiomc PAH and aniomc PSS on curcumin
nanoparticles Figure 4-3 shows a typical zeta potential change dunng the ultrsonic
assisted LbL assembly process Each sample was measured 10 times The standard
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deviation was given by the zeta potential analyzer After the initial -50 ± 2 mV for bare
curcumin particles, PAH adsorption during the first step of nanoparticles synthesis
converts the potential to +30 ± 2 mV Next, anionic PSS adsorption changes the
potential to -53 ± 2 mV, followed by +20 ± 2 mV with PAH, and again -50 ± 2 mV with
PSS Therefore, a multilayer coating of polycations and polyamons with composition of
(PAH/PSS)2 was coated onto the curcumin nanoparticles and the enhanced surface
potential of -50 mV was reached This value is well above commonly accepted colloidal
stability threshold of (±) 30 mV [149]
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Figure 4-3 ^-potential alternation during LbL-shell formation of
catiomc PAH and anionic PSS on curcumin
nanoparticles Standard deviation shows the same
sample run 10 times on zeta potential analyzer

Separate QCM analysis of the LbL assembly process for these polyelectrolytes
on silver plated 9-MHz Quartz Crystal Microbalance resonators (USI-System Instr,
Japan) demonstrated a thickness increment of 2 0 ± 0 3 nm for a PAH/PSS bilayer, and
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the total thickness of the two-bilayer shell on the curcumin nanoparticles may be
estimated as ca. 4 nm. Any shell composition may be achieved with further alternate
adsorption of polycations and polyanions [149].
In another experiment, curcumin nanocapsules with two bilayer shells of
biocompatible protein materials were produced. A positive layer in the shell was
generated using protamine sulfate (PS), while bovine serum albumin (BSA) formed a
negative layer. Total composition produced was (PS/BSA)2. For these LbL
nanocapsules, zeta potential also regularly alternates between +30 mV and -50 mV
providing high colloidal stability of the samples [149]. The dispersion of the
nanoparticles with the concentration of 0.2 g/mL was stored in DI water for two weeks
without precipitation.
The yield of the nanoparticles was about 30-40 % which means that, if curcumin
concentration at the beginning of the process was typically 1 mg/mL, then, in the
product, it was of about 0.3-0.4 mg/mL.
Figure 4-4 shows SEM image of the formed curcumin nanoparticles. One can
see that, in diluted dispersions, the nanoparticles' size is from 50-120 nm (left) and,
upon the drying of the concentrated sample, some aggregation occurs (right image).

Figure 4-4 SEM image of the formed curcumin nanoparticles (left)
diluted sample, and (right) concentrated sample
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4.3 Nanoformulation of Pachtaxel
Pachtaxel (Figure 4-5) is an efficient anti-cancer drug, but due to very low
solubility, there is not effective way for its delivery However, with pachtaxel
nanoformulation it is feasible to increase the drug concentration a hundred times (up to
a few mg/mL)

Figure 4-5 Structural formula for pachtaxel

Figure 4-6 shows a typical zeta potential change during the assembly Each
sample was measured 10 times The standard deviation was given by the zeta potential
analyzer

One can see the zeta potential changes for the LbL assembly of

polyelectrolyte multilayer shell on pachtaxel nanoparticles

Imtially, the surface

potential of the pachtaxel nanoparticles was -21 mV After deposition of the first
catiomc PAH layer (with simultaneous ultrasomcation) we obtained the particle surface
potential of 24 ± 3 mV After deposition of the second layer, anionic polyelectrolyte
layer (PSS), we increased the magnitude of zeta potential to 41 ± 3 mV, and finally, at
the last deposition step a coating with biodegradable chitosan/algmic acid (blue line) or

45

albumin (red line) gave us a strong negative surface charge of the encapsulated
pachtaxel of - 46 ± 4 mV and -32 ± 3 mV This high surface potential provided for the
stability of the developed pachtaxel nanocoUoids for at least two weeks at
concentrations of 0 5 mg/mL
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Figure 4-6 ^-potential of pachtaxel coated with two different
bilayers of PAH-PSS-PAH-BSA and PAH-PSSchitosan-algmic acid (using top-down approach)
Standard deviation shows the same sample run 10 times
on zeta potential analyzer

In Figure 4-7, one can see the SEM image of the initial micromzed sample of
pachtaxel It consists of needle-like rods with diameter of ca 100 nm and length of 2-3
um Dunng sonication-assisted LbL encapsulation, we obtained rather homogeneous
particles with overage sizes of 100 x 100 x 200 nm This particle suspension is
collapsed dunng the drying of the sample but the aqueous dispersion itself is stable It is
interesting, that due to very low solubility, it is possible to keep the pachtaxel sample
without dissolution for weeks because in such a restncted volume the supernatant
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saturation is reached preventing further particles dissolution. Only in a big solvent
volume (under sink release conditions), can pachtaxel nanoparticles be partially or
completely dissolved. These particles are less than 300 nm and are in accordance with
the minimum particle size allowed by FDA for medical injections.
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Figure 4-7 SEM image of orginal pachtaxel (left) and after
ultrasound assisted LbL encapsulation with
PAH/PSS/chitosan/alginic acid (right)
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CHAPTER 5
DRUG NANOPARTICULATION VIA BOTTOM-UP APPROACH
This technology is our new invention It was disclosed to LaTech 1) Z Zheng,
Y Lvov "Somcation synthesis of polyelectrolyte coated nanoparticles through mixing
molecular solutions with bad solvents," September 30, 2008-27, and 2) Y Lvov, Z
Zheng, V Torchihn "Pachtaxel and atavoquone nanoparticle production through
ultrasonication with gradual desolvation assisted with polycation coating Synthesis of
the mixed drugs nanoparticles," December 1, 2008-30 US patent application by V
Torchihn, Y Lvov, Z Zheng "Stable Aqueous NanocoUoids of Pachtaxel and
Atavoquone," was filed by Louisiana Tech University and Northeastern University on
April 25, 2009 Some sections of this chapter were published in a paper written by the
author of this dissertation and will be conespondmgly refened [149] Z Zheng, X
Zhang, D Carbo, C Clark, C-A Nathan, Y Lvov, Langmmr, v 26, 7679-7681, 2010
"Somcation assisted synthesis of polyelectrolyte coated curcumin nanoparticles "

5.1 Methodology
The drug powder was dissolved in ethanol/water solution After drug has been
completely dissolved, we added aqueous polycations, poly(allylamme hydrochlonde)
(PAH) or biodegradable protomme sulfate (PS), and started ultrasonication with a
UIPIOOO, Hielscher instrument, at energy density of 100 Wt per mL of solution During
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the somcation, water was slowly added into the solution Because of the added water,
the solvent becomes more polar, causing a decrease of drug solubility, and eventually,
its concentration exceeds the solubility threshold resulting in the drug supersaturated
conditions Then, crystal nucleation starts Under high power ultrasonication, the drug
particle growth ceases at the initial stages [149] An adsorption of polyelectrolytes onto
the drug nanocrystals establishes a barner for their further growth and aggregation The
minimum amount of polyelectrolytes needed for complete coverage was calculated in
Appendix A Obtained drug crystal particles were stable and did not aggregated after
somcation was stopped We assume that it was because of the increase of surface charge
provided by the adsorbed polyelectrolyte layer After 45 min of somcation, drug
nanocrystals were separated from the solution by centnfugation and re-suspended in DI
water Additional polyelectrolyte multilayers were built on the curcumm nanoparticles
by alternate adsorption of polyamons and polycations (LbL shell assembly) For
biocompatible capsules, an alternate adsorption of catiomc protamine sulfate (PS) and
anionic bovine serum albumin (BSA) were used (Figure 5-1)
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Figure 5-1 Scheme of the bottom-up curcumin LbL
nanoformulation

The drug was dissolved in 60 % ethanol at a concentration of 2 mg/mL We
present here the results for low solubility anti-cancer drugs curcumin and pachtaxel
Ultrasonication was applied for 45 min while slowly adding water at the rate of 0 2
mL/min [149]

5.2 Curcumin Nanoformulation
5.2.1 Nanocurcumm preparation
The drug/shell multilayer structure is curcumin/PS/BSA/PS/BSA
The following expenmental step-by-step sequence was used to prepare
nanoparticles of curcumin
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1)

10 mg curcumin were dissolved in 10 ml of 60 % ethanol/water
(optionally, we also used acetone)

2)

The solution was presomcated for 5 mm to completely dissolve the
curcumin

3)

6 mL of 0 2 mg/mL aqueous catiomc PS, pH 6 5 were slowly added at a
speed of 0 5 mL/min during 30 mm somcation This is the key step of the
procedure initiating the particle nucleation

4)

The nanoparticles were washed twice with DI water using 7000 rpm
centnfugation to separate the nanoparticles from supernatant

5)

3 mg of aniomc BSA were added to the mixture and allowed to adsorb for
10 min

6)

The nanoparticles were washed twice with DI water using 7000 rpm
centnfugation before coating with aqueous cationic PS

7)

3 mg of PS were added to the mixture and allowed to adsorb for 10 min

8)

Steps 4-7 were repeated to achieve a given number of layers

Figure 5-2 shows a typical zeta potential change during the ultrsonic assisted
LbL assembly process Each sample was measured 10 times The standard deviation
was given by the zeta potential analyzer Due to the adsorption of cationic PAH, the
surface potential of these nanoparticles was positive ca +30 mV Further coating with
PSS increased the zeta potential magmtude to -52 ± 4 mV

High surface charge

increases colloidal stability for this formulation For example, in an aqueous curcumin
nanocolloid of 0 5 mg/mL concentration a stable dispersion of the drug was preserved
for one month In Appendix B, we calculated the average distance between particles
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under different conditions Low concentration means longer distance between particles,
which usually means better stability
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Figure 5-2 Particle ^-potential alternation dunng LbL coating of
curcumin (pH 6 5) Standard deviation shows the same
sample run 10 times on zeta potential analyzer

Curcumin nanoparticles of rectangular shape were obtained Edges from 60 nm
to 90 nm (Figure 5-3) and average edge size of 80 ± 20 nm were estimated with SEM
imaging processing software Quartz PCI (Hitachi) and light scattenng experiments
(Brookhaven Instruments, Co , ZetaPlus) The rectangular shape of the nanoparticles is
associated with the crystalline nature of the obtained curcumin particles [149]
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Figure 5-3 SEM images of initial curcumin powder (left) and
resulting curcumin nanocolloid (right)

To examine the crystal structure of the curcumin nanoparticles, X-ray powder
diffraction analysis was carried out with a Bruker-D8 XRD instrument. Bragg peak
positions in the X-ray pattern obtained from the dried nanoparticles powder coincided
with the peak positions for bulk curcumin powder, but the peaks were wider due to
smaller crystallite size (Figure 5-4). These X-ray data indicate that the crystal structure
of curcumin was preserved, and polycations added during drug crystal formation did not
form a complex with curcumin molecules but only covered the crystals surface. We
assume that polycations were layered predominantly on the crystal surface, as it follows
from electrophoretic (^-potential) data given below [149].
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Figure 5-4 X-ray diffraction spectra for micromzed curcumm
powder (upper spectrum) and for nanoformulated
curcumin (lower spectrum)

5 3 Pachtaxel Nanoformulation
5.3.1 Preparation of nanopachtaxel
The following experimental step-by-step sequence was used to prepare
nanoparticles of pachtaxel
1)

10 mg of pachtaxel were dissolved in 10 mL of 60 % ethanol/water
solvent

2)

The mixture was presomcated for 5 mm to completely dissolve pachtaxel

3)

6 mL of aqueous 0 2 mg/mL cationic PS (pH 6 5) was added at a speed of
0 5 mL/min dunng 45 mm somcation This is the most important stage of
the formulation
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4)

The nanoparticles were separated from supernatant using 7000 rpm
centnfugation for 10 min and washed twice with DI water Then the
nanoparticles were redispersed in 10 ml of DI water

5)

For next BSA layer, 3 mg BSA were admixed to the dispersion for 10 min

6)

Step 4 was repeated

7)

A layer of catiomc protamine sulfate was deposited in the same way as in
step 5

8)

Step 4 was repeated

9)

Steps 5-8 were repeated to obtain the desired coating structure

Pachtaxel was dissolved in a "good" solvent (60 % ethanol/water or 60 %
acetone/water) After dissolution of the drug at high concentration, ultrasonication was
started with aqueous polycation slowly added to the solution With an increase of water
concentration, solubility of pachtaxel decreased, reached saturation and the nucleation
began resulting in the formation of nano-size particles
Powerful somcation prevents formation of larger drug particles and polycation
adsorption provides for a surface charge sufficient for colloidal stability After a 45 min
treatment, the drug particles were centnfuged at 7,000 rpm for 10 mm and re-suspended
in distilled water The second layer of anionic polyelectrolytes was deposited to
maximize the capsule surface potential Nonreacted polyanions were removed by
centnfugation and pachtaxel nanoparticles with the average particle size of 100 nm
were obtained Additional polyelectrolyte layers may be further built up on the drug
nanoparticles using the traditional LbL process without somcation Obtained pachtaxel
nanocolloid was kept in a small volume of saturated solution to prevent drug release
[149]
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Figure 5-5 shows a typical zeta potential change dunng the Ultrsonic assisted
layer-by-layer assembly process Each sample was measured 10 times The standard
deviation was given by the ZetaPlus zeta potential analyzer (Brookhaven Instruments,
Co) The alternated zeta potential dunng formation of LbL nanoshells on pachtaxel
nanocores has a minimal potential of-35 mV
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Figure 5-5 ^.-potential change dunng the LbL encapsulation of
pachtaxel Standard deviation shows the same sample
run 10 times on zeta potential analyzer

Figure 5-6 shows SEM image of the resulting nanocapsules with average
diameter of 90 ± 20 nm
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Figure 5-6 SEM image of pachtaxel nanoparticles with shells of
(PS/PSA)2 (left); same sample showing aggregation of
particles at another site (right)

Figures 5-7 shows the SEM images of pachtaxel particles prepared with the
bottom-up approach, then using centrifuge to separate large particles and small
particles.

Figure 5-7 SEM image of pachtaxel in 60 % ethanol sonicate for
45 min before (left) and after (right) centrifuge

CHAPTER 6
PROCESS OPTIMIZATION
6.1 Ultrasonication Time
The first parameter we optimized was somcation time It is logical to assume
that the longer the somcation, the smaller particles one can get However, in the "topdown" approach, even many hours of somcation did not result in particles less than 200
nm Probably, there is a limitation preventing further splitting of the drug particles In
ref [151], it was suggested that this minimal size may be related to the nucleation size
of vapor bubbles during somcation

The only imporvement which we suggest m future

work could be a modification of the cavitation process in somcation by changing
solution properties and vapor bubble formation conditions (for example, with increased
pressure) Finally, the optimized somcation time for the nanoformulation of curcumin
and pachtaxel was chosen to be 30-45 min Another factor, requinng the limitation of
somcation time is sample pollution with depleted submicron particles of titanium oxide
This pollution is developing with somcation times above one hour and then additional
sample punfication to eliminate titanium alloy particles is needed Fortunately, it is
relatively easy due to different particle densities As shown in Figure 6-1, the particle
size decreases when the somcation time increase The result was achieved after seven
measurements at each data point The standard deviation was given by the 90Plus
particle sizer
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Figure 6-1 Decrease of curcumin nanoparticles size as a function of
somcation time in the presence of polycation Standard
deviation shows the same sample run seven times on
90Plus particle sizer

6.2 Water Add-m Speed and Drug Concentration
To minimize the curcumin particle size, we prepared a series of samples
processed under vanous conditions (different ethanol/water ratios, drug concentrations,
ultrasonication power, time, and speed of the solvent worsening for crystallization
initiation) Two major factors that affect the crystal size were the rate of water addition
(speed of the solvent worsemng) and an initial curcumin concentration These factors
were optimized Figure 6-2 gives the dependence of particle size on the rate of water
addition The result was achieved after seven measurements at each data point The
standard deviation shows the same sample run seven times on 90Plus particle sizer
(Brookhaven Instruments, Co)

59

400
350

<•

300
?
o.
S
c/3
2.
o

250

|

100

-

50

-

200

3S*l

150

o

1

1

1

1

i

\J

0

1

2
3
4
Water add-m speed (ml/mm)

5

Figure 6-2 Dependence of curcumin particle size on water addition
rate Standard deviation shows the same sample run
seven times on 90Plus particle sizer

The water addition rate was varied from 0 05 mL/min up to 0 4 mL/mm for the
sample volume of 50 mL, and the higher rate resulted in the formation of larger
particles We observed particles of ca 320 nm average size at 0 4 mL/mm rate versus
ca 120 nm particles for the 0 05 mL/min rate
An increase of curcumm concentration in the initial solution also resulted in
larger nanoparticles as shown in Figure 6-3 The result was achieved after seven
measurements at each data point The standard deviation shows the same sample run
seven times on 90Plus particle sizer (Brookhaven Instruments, Co) Slightly larger
sizes of curcumin nanoparticles, as obtained with the light scattering technique (ca 100
nm) as compared with mean 80 nm size average over thirty particles in the SEM image
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may be explained by the fact that light scattenng is more sensitive to the admixture of
larger particles in the sample, which were excluded in the SEM estimations [149]
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Figure 6-3 Dependence of curcumin particle size on curcumin
concentration Standard deviation shows the same
sample run seven times on 90Plus particle sizer

CHAPTER 7
DRUG RELEASE
We use a set of side-by-side diffusion cells (PermeGear, Inc) to measure the
drug release profile
The setup is shown in Figure 7-1 We use a 0 1 urn membrane to separate the
two chambers The joint between the sections was sealed with silicone gel We fill the
receptor chamber with DI water and fill the donor chamber with the drug sample and
start timing After a certain time penod we take out all the solution in the receptor
chamber and refill it with DI water again Each solution that is taken out from the
receptor chamber is labeled (si, s2,

s(n-l)) then measured for drug concentration

with UV spectrophotometer (Agilent 8453) A standard curve is measured earlier to
establish the relationship between concentration and absorption, and a linear
relationship was found At the end of the release test, both solutions from the receptor
chamber (sn) and the donor chamber (sd) were taken out and measured for
concentration The release rate was established by accumulating the amount of the drug
taken out from the receptor at time x
Total amount of drug =S 1+S2+

+Sn+Sd

Release rate at time x= (S1+S2

+Sx) / Total amount of drug
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Figure 7-1 Release test side-by-side diffusion cell set up (Scheme
of side-by-side cells kindly provided by PermeGear, Inc )

7 1 Curcumin Release from Nanocapsules
The drug release profile of the curcumin LbL-nanocolloids with the (PS/BSA)2
coating was analyzed in a diffusion chamber (sink conditions) (Figure 7-2) 50 % drug
release from LbL coated nanoparticles was reached in seven hours and 60 % release
was reached withm ca 20 hours This release is slower than for nano-curcumin powder
without the LbL shell or the original micromzed curcumin We have to emphasize that
the main goal of our work is not slowing down of the drug release rate but the
formulation of stable drug nanocoUoids with injectable particle size (below 300 nm)
However, a slower release time is useful and is an indirect proof of the shell formation
providing a diffusion bamer for the particles and slowing down their dissolution
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Figure 7-2 Release profiles of curcumin in ongmal micropowder
form, after nanoparticulation and prepared with LbL
nano-encapsulation (the shell composition (PS/BSA)2)

The release profile fits the Peppas model M,/Mx

= Kt" , where M, is the

amount of drug released at time t, Mm is the amount of drug released at infinite time, n
is the exponent charactenstic of the release mechamsm, and K is a constant Detail of
the fitting can be seen in Appendix C The obtained value for n less than 0 5 indicates
that the release mechamsm is Fickian diffusion

7.2 Pachtaxel Release from Nanocapsules
The release profiles of the onginal pachtaxel powder, pachtaxel nanocoUoids
with one polycation layer and three polycation/polyamon bilayer coating were analyzed
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in standard sink conditions The fitting of the release curves were accomplished with
exponential Peppas' model Withm eight hours, 70 % of onginal pachtaxel powder was
released (Figure 7-3)
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Figure 7-3 Release curves for the original micronized powder of
pachtaxel, uncoated pachtaxel nanoparticles (only one
PAH layer adsorbed for colloidal stabilization) and
nano-encapsulated pachtaxel with (PAH/BSA)2 shell
composition

Nanoparticulated pachtaxel coated with one polyelectrolyte layer leads to
slightly faster release due to a smaller particle size in nanoformulation, as compared
with the micrometer size of the original pachtaxel Pachtaxel nanocoUoids, coated with
two bilayers of PAH/BSA, showed a lower drug release rate due to the increasing
thickness of the capsule wall For example, in eight hours, only 40 % of the two layers
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coated sample was released as compared with 80 % for the one layer coated sample
The LbL encapsulation technique allows for control of the drug release rate from
polyelectrolytes-stabihzed nanoparticles by changes in the number of coating layers or
the shell composition [148]

CHAPTER 8
CONCLUSIONS
Two methods (top-down and bottom-up) of nanoparticle formulation for low
water-solubility materials were developed and applied for nanoformulation of anticancer drugs curcumin and pachtaxel The resulting drug nanoparticles have a diameter
of 100-220 nm and are stable in water
In the first, top-down method, the drug powder was broken up by ultrasound
through the collapse of microbubbles (with jet fluid and shock waves) By adding
polycations into the solution, the slightly oxidized negative surface of the newly formed
particles was recharged positively to a higher surface potential which prevented
particles from aggregating This approach was proposed earlier, and we applied it to the
new drugs pachtaxel and curcumin, the resulting nanoformulated drug had diameters of
ca 200-250 nm
In this work we pioneered the second bottom-up nanoformulation method The
drag was dissolved m an organic solvent that is miscible with water (ethanol or acetone)
and its nucleation was initiated by the gradual decrease in the solubility of the solution
with addition of aqueous polyelectrolyte The process was assisted by ultrasonication
Similarly to the first method, the polyelectrolytes coating induced higher surface charge
on the formed nanoparticles and provides nanocolloid stability This coating was
extended to achieve multilayer encapsulation through alternate adsorption of oppositely
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charged

synthetic

and biodegradable

polyelectrolytes

(polyallyl amine,

sodium

polystyrenesulfonate, chitosan, bovine serum albumin, protamine sulfate, and alginic
acid) Unlike the commonly used emulsion methods, our ultrasonication assisted layerby-layer nano-encapsulation method allowed for achieving nanoparticles of a much
smaller size We obtained crystalline nanoparticles with an average size of 80 nm, and
zeta potential of+30 mV or -50 mV (depending on the number of polyelectrolyte layers
in the shell), which ensured the stability of the nanocoUoids in water for weeks at a
concentration of ca 0 2 mg/mL Formation of shells with two bilayers of biocompatible
polyelectrolytes allowed for slow drug release during ca 20 hours
The product efficiency of the top-down approach was ca 50 %, which was
higher than the efficiency of the bottom-up approach (ca 20 %) The bottom-up
approach leads to increased losses due to the formation of larger particles at a fast
nucleation rate Larger were removed by centnfugation thus decreasing the yield of the
nanoparticles final product
Ultrasound assisted layer-by-layer nano-encapsulation is a promising technique
to produce stable 1-2 mg/mL concentration nanocoUoids of poor water soluble drugs,
like pachtaxel, curcumin, and others The particle size in such drag formulation is
reduced from the initial tens of micrometers m the drag powders to 100-200 nm which
allow

climcal

injection

Nanoparticle

coating

with

natural

polyelectrolytes

(polysaccharides) has the potential to increase drag circulation time and availability at a
rumor site

Layer-by-layer encapsulation was earned out with

biodegradable

polyelectrolytes protamine sulfate, alginic acid, chitosan and bovine serum albumin
The drag particle size can be optimized using either top-down or bottom-up sonicated
LbL-treatment
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Future work
The stability of nanocoUoids at a concentration of 2 mg/mL in buffers with 0 1
M

salt concentration needs to be improved

Our formulation allowed

stable

nanocoUoids only in solutions with low salt concentrations The free reactive groups of
biocompatible polyelectrolytes (amine or acidic) at the outermost layer may help to bind
PEG for longer particle circulation in blood or receptors for targeted drag delivery
Further process improvement of both top-down and bottom-up techniques can
be achieved by increasing the somcation power Ultrasonication efficiency depends on
the shock wave power released on the drag particle surface due to the collapsing of gas
microbubbles One can choose additives which will increase the number of bubbles and
decompose without damaging the original drug product Another approach to increase
somcation power is working under elevated pressure, which may be reached using a
compressed gas atmosphere New graduate students will work on constructing a high
gas pressure chamber for ultrasonication
For drag nanoparticles targeting, we are planning to use a chemically active
layer (with acidic, amine groups) as the outside LbL coating layer to link antibody to
target drugs to specific cancer cells
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To estimate the minimum amount of polyelectrolyte needed for complete
coverage of nanoparticles we perform the calculation m Table A-1 In this case we
calculate the PAH needed to complete coat 2 g of pachtaxel which have a rectangular
sharp and average edge of 300 nm length

Table A-1 Minimum amount of polyelectrolyte needed for coating
Assume PTX density=

15

g/cm

PTX weight

2 00E-02

g

average single PTX size
average single PTX size nm
volume of PTX=w/p
single PTX volume
number of PTX particle
single PTX surface
total surface
thickness of PAH
thickness of PAH nm
volume of PAH
PAH density
PAH weight
PAH weight in mg

3 00E-05
3 00E+02
1 3333E-02
2 70E-14
4 9383E+11
5 40E-09
2 6667E+03
2 00E-07
2 00E+00
5 3333E-04
16
8 5333E-04
8 5333E-01

cm
nm
cm3
cm3
cm
2

cm
cm
nm
cm3
g/cm
g
mg

APPENDIX B
NANOCOLLOID PARTICLE DISTANCE CALCULATION
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We found that the stability of drag nano colloid was effect by the concentration
of the colloid In general, we found the lower the concentration the better the stability
To estimate the average distance between particles at a certain concentration, we prefer
the calculation in Table B-1 (for sphere sharp) and Table B-2 (for cube sharp)

Table B-1 Average distance between sphere particles
Calculate particle as sphere
Weight of drug in 1ml solution(mg)
Density of drug (mg/ml)
Weight of water (mg)
Concentration (mg/ml)
Size of particles (nm)
Size of particles (cm)
Weight of each particle (mg)
Number of particles
Volume of each particle (round) (ml)
Volume of solution outside a particle(ml)
Volume of each cell (ml)
Distantce cm
Distantce um

Sample 1 Sample 2
05
2
1500
1500
1000
1000
05
2
200
200
0 00002
0 00002
6 28E-12 6 28E-12
7 96E+10 3 18E+11
4 19E-15 4 19E-15
1 26E-11 3 14E-12
126E-11 3 15E-12
0 000232 0 000146
2 324897 1 464593

Sample 3
5
1500
1000
5
200
0 O0002
6 28E-12
7 96E+11
4 19E-15
1 26E-12
1 26E-12
0 000108
1 079121

Table B-2 Average distance between cube particles
Calculate particle as cube
Weight of drug in 1ml solution(mg)
Density of drag (mg/ml)
Weight of water (mg)
Concentration (mg/ml)
Size of particles (nm)
Size of particles (cm)
Weight of each particle (mg)
Number of particles
Volume of each particle (cube) (ml)
Volume of solution outside a particle (ml)
Volum of each cell (ml)
Distantce cm
Distantce um

Sample 1 Sample 2 Sample 3
05
2
5
1500
1500
1500
1000
1000
1000
05
2
5
200
200
200
0 00002
0 00002
0 00002
1 2E-11
12E-11
1 2E-11
4 17E+10 167E+11 4 17E+11
8E-15
8E-15
8E-15
2 4E-11
6E-12
2 4E-12
2 4E-11 6 01E-12 2 41E-12
0 000288 0 000182 0 000134
2 884499 1 817121 1 338866
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To show the result in 3D image we use Matlab 2007 to plot the image The
program code is shown below
%nanoparticles size and distance calculation
%wntten by zhiguo zheng
%PhD student of Biomedical Engmeenng of Louisiana Tech University%
clc
clear all
%draw 3d sphere radius r nm in s nm cube cell
[xsp,ysp,zsp] = sphere(20),
r=200,
d=1079,
s=2000,
xsp=xsp *r,
ysp=ysp *r,
zsp=zsp *r,
for 1 = -s d s,
forj=-s d s,
for k=-s d s,
surface(xsp+i,ysp+j ,zsp+k),
end
end,
end,
axis equal,
view([50,20]),
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The simulation results for 200 nm sphere pachtaxel nanoparticles at concentration of
0 5 and 5 mg/mL are shown in Figure B-1

Figure B-1 Simulation for 200 nm sephere sharp pachtaxel
concentration at 0 5 mg/mL (left) and 5 mg/mL (right)

%nanoparticles size and distance calculation
%wntten by zhiguo zheng
%PhD student of Biomedical Engineering of Louisiana Tech Umversity
clc, clear all,
%draw 3d cubes edge length r nm in distance d nm in a s nm cube cell
x=[0 1 1 0 0 0,1 1 0 0 1 1,1 1 0 0 1 1,0 1 1 0 0 0],
y=[0 0 1 1 0 0,0 1 1 0 0 0,0 1 1 0 1 1,0 0 1 1 1 1],
z=[0 0 0 0 0 1,0 0 0 0 0 1,1 1 1 1 0 1,1 1 1 1 0 1],
r=200,
d=1339,
s=3000,
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x=x *r,
y=y *r,
z=z *r,
for 1 = -s d s,
forj=-s d s,
for k--s d s,
surface(x+i,y+j,z+k),
end,
end,
end,
axis equal,
view([35,30]),
The simulation results for 200 nm cube sharp pachtaxel nanoparticles at concentration
of 0 5 and 5 mg/mL are shown in Figure B-2

Figure B-2 Simulation for 200 nm cube sharp pachtaxel
concentration at 0 5 mg/mL (left) and 5 mg/mL (right)

APPENDLX C
RELEASE MODEL FITTING
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For release curve in Figure 7-2 we use OriginPro 8 1 software to fit the
expenment data with modmg equation
In this study, we use Ritger-Peppas' empirical Equation

Figure C-l shows the fittmg of expenment result using Ritger-Peppas' empirical
equation The fitting results are shown in Table C-l

Table C-l Fitting results for the curcumin release profile
Model
Equation
Reduced Chi-Sqr
Adj R-Square
Nano curcumin
Nano curcumin
Orginal curcumin
Orginal curcumin
Curcumin/(PS/BSA)2
Curcumm/(PS/BSA)2

Ritger-Peppas
y = a*x
3 48E-04 1 80E-04
0 99468 0 99455
Value
a
0 34387
b
0 21044
a
11 00387
b
0 01274
a
0 18261
b
0 24341

4 49E-04
0 99019
Standard enor
0 10581
0 03356
37 90579
0 04171
0 05416
0 0346
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Figure C-l Fitting result for curcumin release

Figure C-2 shows the fitting of experiment result using Ritger-Peppas' empirical
equation The fittmg results are shown in Table C-2

Table C-2 Fitting results for the pachtaxel release profile
Model
Equation
Reduced Chi-Sqr
Adj R-Square
Nano pachtaxel
Nano pachtaxel
Orginal pachtaxel
Orginal pachtaxel
Pachtaxel/(PAH/BSA)2
Pachtaxel/(PAH/BSA)2

Ritger-Peppas
Y= aV
5 35939
4 71E+00
0 93513
0 93758
Value
a
10 72209
b
0 33469
a
9 46E+00
b
0 33125
a
11 31214
b
0 23387

2 45E+00
0 9103
Standard Error
1 38742
0 02507
1 27E+00
0 02535
1 30579
0 02159
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